Fabio Ferrarelli

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Fabio Ferrarelli sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).

2 total trials 2 currently recruiting upper half by trial count

Fabio Ferrarelli: 2 sponsored US clinical trials, 2 recruiting.

Fabio Ferrarelli sponsors 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting. The most-studied condition in this pipeline is Schizophrenia, with 2 trials.

Mid-pack sponsor footprint

Fabio Ferrarelli is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Open and recent trials

2 total, page 1 of 1

RECRUITING NA

Restoring Spindle and Thalamocortical Efficiency in Early-Course Schizophrenia Patients Using Auditory Stimulation

NCT05956951
RECRUITING NA

Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia

NCT05102929

Therapeutic Areas

Schizophrenia 2

What is open in the Fabio Ferrarelli pipeline

2 recruiting of 2 indexed (100% open).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Schizophrenia (2 trials), 0 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Fabio Ferrarelli: open-pipeline peers nationwide

Peers matched on 2 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

Fabio Ferrarelli sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 1.522.533.544.5 0%50%100%150% Total trials Recruiting share Fabio Ferrarelli1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO HealthAAVantgarde Bio SrlAcorn BiolabsAcrivon TherapeuticsADARx Pharmaceuticals
Fabio Ferrarelli sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Fabio Ferrarelli sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 2 trials (± recruiting share)

Sponsors near 100% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Fabio Ferrarelli page

2 registered trials is a research-attention snapshot, not an endorsement of Fabio Ferrarelli or any single study.

  • 2 of Fabio Ferrarelli's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Schizophrenia is the condition Fabio Ferrarelli studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Schizophrenia trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Fabio Ferrarelli pipeline card: 2 registered trials from official public datasets.Report a data error.